scholarly journals Biofield Energy Healing Based Herbomineral Formulation: An Emerging Frontier in Cosmetic Medicine

2017 ◽  
Vol 5 (3) ◽  
pp. 36
Author(s):  
Dezi Ann Koster
2021 ◽  
Vol 6 (2) ◽  
pp. 1-4
Author(s):  
Velthuis PJ

Most popular fillers in cosmetic medicine are hyaluronic acid based. These comprise over 90% of the market and come with the advantage to be soluble in case of complications. Other fillers are contained in the group of bio-stimulatory fillers. They exert a secondary volumizing effect by provoking a low-grade inflammatory response that produces extra collagen. Examples are calcium-hydroxyapatite and L-poly-lactid acid. Finally autologous fat is being used as a filling substance (lipofilling). The gravest complications with fillers are intravascular injections. In particular when injected in arteries fillers can block blood flow and lead to skin necrosis or vison loss in case the material occludes the Central Retinal Artery (CRAO). Two opposing theories about the nature of arterial occlusion exist. One based on Ian Taylor idea of choke anastomoses assume vasoconstriction induced by the filler, both of the primary offended artery and its anastomosing vasosomes. In this case resolving the hyaluronic acid filler with the enzyme hyaluronidase at the primary occluding location would suffice. This is done under ultrasound guidance. The other theory assumes displacement of parts of the filler to end arterioles. Then, the whole affected area has to be flooded with large dosages of hyaluronidase. Obstructions with fillers based on other materials cannot be resolved. It seems logical to prevent intra-arterial filler injection by duplex sonography detection of the course of arteries prior to injection. Ultrasound has additional advantages for cosmetic doctors such as recognizing remains of previously injected filler. It also can give feedback on a physician’s ability to inject filler in the correct subdermal location.


2019 ◽  
Vol 2 (2) ◽  
pp. 14-24
Author(s):  
Dahryn Trivedi ◽  
Mahendra Kumar Trivedi ◽  
Alice Branton ◽  
Gopal Nayak ◽  
Snehasis Jana

Hydroxypropyl β-Cyclodextrin (HPBCD) used in food, pharmaceutical, chemical industries, as well as environmental, and agriculture engineering. But the major issue related to HPBCD is the low solubility profile. In this study, the influence of the Consciousness Energy Healing Treatment (the Trivedi Effect®) on the physicochemical properties of HPBCD was evaluated using spectroscopic and calorimetric analytical techniques. The test sample (HPBCD) was divided into control sample and treated sample. The control sample did not receive the Biofield Energy Treatment. Whereas, the treated sample received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Dahryn Trivedi. The particle size values of the treated sample were decreased by 3.28%(d10), 1.36%(d50), 0.45%(d90), and 1.04%{D(4,3)}; therefore, the specific surface area was increased by 1.9% compared with the control sample. The evaporation temperature of the treated HPBCD sample was significantly decreased by 19.89%; however, the latent heat of evaporation and latent heat of fusion were significantly increased by 56.27% and 47.41%, respectively compared with the control sample.The total weight loss in the treated HPBCD was decreased by 5.11%; whereas, the residue amount was significantly 309.67% more compared to the control sample.The results indicated that the Trivedi Effect® might have produced a new form of HPBCD which may show better thermal stability, solubility, dissolution rate, and bioavailability. This new form of HPBCD would be more useful for improvement of solubility of the lipophilic drug, preparation of cholesterol free food products, weight loss supplements, anti-obesity medication, stabilize volatile and unstable compounds, and other manufacturing industry using it as a raw material.


2021 ◽  
Vol 1 (1) ◽  
Author(s):  
Orien L Tulp

Onabotulinumtoxin A (Botox®) is a parasympathetic autonomic blocking agent which acts as an inhibitor of the neuromuscular transmitter acetylcholine release and as a neuromuscular blocking agent, thereby inducing relaxation of selected muscle fibers for a duration of up to approximately 3 months duration. First approved by the FDA in 1989 and approved for further applications since 1991, the drug has now gained wide acceptance in cosmetic and other therapeutic applications, where the autonomic neurotransmitter acetylcholine blockade can bring about favorable cosmetic responses, particularly in the field of dermatology and cosmetic medicine. Since the original application of Onabotulinumtoxin A was approved for clinical use as a cosmetic agent, numerous additional applications have been approved by the FDA, all of which involve acetylcholine-mediated neuromuscular actions.


Sign in / Sign up

Export Citation Format

Share Document